AMICUS THERAPEUTICS INC's ticker is FOLD and the CUSIP is 03152W109. A total of 226 filers reported holding AMICUS THERAPEUTICS INC in Q3 2023. The put-call ratio across all filers is 0.62 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $671,244 | -2.6% | 55,201 | +0.6% | 0.00% | 0.0% |
| Q2 2023 | $689,343 | +19.7% | 54,884 | +5.7% | 0.00% | 0.0% |
| Q1 2023 | $575,959 | -19.7% | 51,935 | -11.6% | 0.00% | -33.3% |
| Q4 2022 | $716,996 | +27.4% | 58,722 | +8.8% | 0.00% | +50.0% |
| Q3 2022 | $563,000 | -0.5% | 53,997 | +2.3% | 0.00% | 0.0% |
| Q2 2022 | $566,000 | -23.6% | 52,786 | -32.6% | 0.00% | 0.0% |
| Q1 2022 | $741,000 | -33.6% | 78,293 | -19.0% | 0.00% | 0.0% |
| Q4 2021 | $1,116,000 | +28.9% | 96,628 | +6.6% | 0.00% | 0.0% |
| Q3 2021 | $866,000 | -22.6% | 90,643 | -21.9% | 0.00% | -33.3% |
| Q2 2021 | $1,119,000 | +8.0% | 116,030 | +10.7% | 0.00% | 0.0% |
| Q1 2021 | $1,036,000 | -53.8% | 104,846 | +7.9% | 0.00% | -62.5% |
| Q4 2020 | $2,244,000 | +118.1% | 97,187 | +33.4% | 0.01% | +60.0% |
| Q3 2020 | $1,029,000 | -9.9% | 72,861 | -3.8% | 0.01% | -16.7% |
| Q2 2020 | $1,142,000 | +146.7% | 75,729 | +51.3% | 0.01% | +100.0% |
| Q1 2020 | $463,000 | -47.1% | 50,058 | -44.2% | 0.00% | -25.0% |
| Q4 2019 | $875,000 | +11.2% | 89,788 | -8.4% | 0.00% | 0.0% |
| Q3 2019 | $787,000 | -31.6% | 98,070 | +6.4% | 0.00% | -42.9% |
| Q2 2019 | $1,151,000 | -12.3% | 92,209 | -4.5% | 0.01% | -12.5% |
| Q1 2019 | $1,313,000 | +63.1% | 96,579 | +14.9% | 0.01% | +33.3% |
| Q4 2018 | $805,000 | -33.6% | 84,059 | -16.2% | 0.01% | -25.0% |
| Q3 2018 | $1,212,000 | -25.5% | 100,289 | -3.7% | 0.01% | -27.3% |
| Q2 2018 | $1,627,000 | -1.3% | 104,142 | -5.0% | 0.01% | 0.0% |
| Q1 2018 | $1,649,000 | +0.2% | 109,655 | -4.1% | 0.01% | 0.0% |
| Q4 2017 | $1,646,000 | +4.9% | 114,365 | +9.9% | 0.01% | -21.4% |
| Q3 2017 | $1,569,000 | +81.2% | 104,050 | +20.9% | 0.01% | +55.6% |
| Q2 2017 | $866,000 | +31.4% | 86,041 | -6.8% | 0.01% | +28.6% |
| Q1 2017 | $659,000 | +13.4% | 92,366 | -21.0% | 0.01% | +16.7% |
| Q4 2016 | $581,000 | -24.3% | 116,911 | +12.7% | 0.01% | -45.5% |
| Q3 2016 | $768,000 | +27.8% | 103,718 | -5.8% | 0.01% | +37.5% |
| Q2 2016 | $601,000 | -33.4% | 110,154 | +3.1% | 0.01% | -33.3% |
| Q1 2016 | $903,000 | -20.7% | 106,863 | -8.9% | 0.01% | -14.3% |
| Q4 2015 | $1,138,000 | -19.9% | 117,318 | +15.6% | 0.01% | -30.0% |
| Q3 2015 | $1,420,000 | +12.5% | 101,529 | +13.8% | 0.02% | +17.6% |
| Q2 2015 | $1,262,000 | +50.6% | 89,209 | +15.9% | 0.02% | +70.0% |
| Q1 2015 | $838,000 | +63.4% | 76,986 | +24.8% | 0.01% | +66.7% |
| Q4 2014 | $513,000 | +701.6% | 61,706 | +100.5% | 0.01% | +500.0% |
| Q1 2014 | $64,000 | -24.7% | 30,782 | -16.0% | 0.00% | -50.0% |
| Q3 2013 | $85,000 | +25.0% | 36,636 | +26.0% | 0.00% | +100.0% |
| Q2 2013 | $68,000 | – | 29,081 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Palo Alto Investors LP | 10,524,022 | $127,972,108 | 12.11% |
| Perceptive Advisors | 27,692,917 | $336,745,870 | 11.23% |
| Redmile Group, LLC | 16,944,621 | $206,046,591 | 9.80% |
| Finepoint Capital LP | 1,489,025 | $18,106,544 | 9.02% |
| CM Management, LLC | 450,000 | $5,472,000 | 5.81% |
| Avoro Capital Advisors LLC | 27,400,000 | $333,184,000 | 5.20% |
| MPM BioImpact LLC | 716,139 | $8,708,250 | 2.32% |
| Artal Group S.A. | 4,062,567 | $49,401 | 2.12% |
| SECTORAL ASSET MANAGEMENT INC | 803,464 | $9,770,122 | 1.90% |
| GREAT POINT PARTNERS LLC | 857,000 | $10,421,120 | 1.90% |